NCT04995042 2023-09-21A Phase 1 Dose Escalation and Expansion Study Of SHR7280 In Subjects With Hormone Sensitive Prostate CancerJiangsu HengRui Medicine Co., Ltd.Phase 1 Completed12 enrolled